Therapy Detail

Therapy Name AZD6738 + Olaparib
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AZD6738 ATR Inhibitor 10 AZD6738 is an inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents, potentially resulting in tumor regression (PMID: 26517239).
Olaparib Lynparza AZD2281|KU-0059436 PARP Inhibitor (Pan) 17 Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for use in patients with germline BRCA-mutated advanced ovarian cancer, germline BRCA-mutated and ERBB2 (HER2)-negative breast cancer, and advanced epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutations (
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ATM loss head and neck cancer predicted - sensitive AZD6738 + Olaparib Preclinical - Cell culture Actionable In a preclinical study, the combination of AZD6738 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating cell death in head and neck cancer cells harboring ATM loss in culture (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C60). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02264678 Phase Ib/II AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting
NCT03330847 Phase II Adavosertib + Olaparib Olaparib AZD6738 + Olaparib To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy Recruiting
NCT02576444 Phase II Adavosertib + Olaparib Olaparib Olaparib + Vistusertib Capivasertib + Olaparib AZD6738 + Olaparib OLAParib COmbinations (OLAPCO) Recruiting
NCT03787680 Phase II AZD6738 + Olaparib Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) Not yet recruiting
NCT03682289 Phase II AZD6738 + Olaparib Olaparib Phase II Trial of AZD6738 Alone and in Combination With Olaparib Recruiting
NCT03462342 Phase II AZD6738 + Olaparib Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI) Recruiting